Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.

Direct oral anticoagulant therapy reduces the 24-month risk of stroke, embolism, bleeding, or cardiovascular death by 69% in intermediate-risk atrial fibrillation patients.

• Why it matters: Current guidelines recommend anticoagulation for these patients, but evidence from randomized trials has been limited, creating uncertainty about benefits and risks.
• What they did: A multicenter trial in South Korea randomized 1803 patients with intermediate stroke risk to receive DOACs or no anticoagulation, tracking major cardiovascular events over two years.
• The result: DOAC therapy significantly lowered the primary endpoint incidence to 0.5% versus 1.5% in controls, demonstrating its effectiveness and safety in reducing adverse outcomes in this population.